Royalty Pharma plc (NASDAQ:RPRX) Holdings Decreased by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 36.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 460,183 shares of the biopharmaceutical company’s stock after selling 261,144 shares during the period. Handelsbanken Fonder AB owned about 0.08% of Royalty Pharma worth $11,739,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of RPRX. Keene & Associates Inc. increased its holdings in Royalty Pharma by 1.9% in the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 370 shares during the last quarter. Blue Trust Inc. grew its position in Royalty Pharma by 31.3% in the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 376 shares in the last quarter. Sanctuary Advisors LLC increased its stake in shares of Royalty Pharma by 0.9% during the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock worth $1,068,000 after purchasing an additional 388 shares during the last quarter. Aurora Investment Counsel raised its holdings in shares of Royalty Pharma by 1.0% during the 3rd quarter. Aurora Investment Counsel now owns 50,441 shares of the biopharmaceutical company’s stock valued at $1,427,000 after purchasing an additional 512 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Royalty Pharma by 31.4% in the 4th quarter. GAMMA Investing LLC now owns 2,471 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 590 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on RPRX shares. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.60.

Royalty Pharma Stock Up 0.3 %

Royalty Pharma stock opened at $33.42 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $33.69. The firm has a fifty day moving average price of $29.18 and a two-hundred day moving average price of $27.94. The firm has a market cap of $19.26 billion, a price-to-earnings ratio of 23.05, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be paid a $0.22 dividend. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 annualized dividend and a dividend yield of 2.63%. Royalty Pharma’s dividend payout ratio (DPR) is presently 57.93%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.